Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiki Niimi

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Biochemical and Biophysical Research Communications|December 6, 2022
A pilot study assessing sphingolipids and glycolipids dysmetabolism in idiopathic normal pressure hydrocephalusTatsuro Mutoh, Yoshiki Niimi, Shinji Ito, et al.
Journal of Medical Internet Research|July 22, 2021
Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational StudyKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease : JAD|April 21, 2026
Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims databaseSaki Nakashima, Kenichiro Sato, Yoshiki Niimi, et al.
Biochemical and Biophysical Research Communications|December 28, 2020
Galabiosylceramide is present in human cerebrospinal fluidHisako Akiyama, Mitsuko Ide, Toshiyuki Yamaji, et al.
Molecular and Cellular Biochemistry|July 22, 2025
Cerebrospinal fluid sphingolipid and sterol metabolite profiles of neurologically normal subjectsYoshiki Niimi, Akihiro Ueda, Hisako Akiyama, et al.
Journal of Parkinson'S Disease|November 20, 2020
Cerebrospinal Fluid Profiles in Parkinson's Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 FragmentYoshiki Niimi, Yasuaki Mizutani, Hisako Akiyama, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation StudyKenichiro Sato, Ryoko Ihara, Masanori Kurihara, et al.
Neurology|December 10, 2013
Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathySayuri Shima, Naoki Kawamura, Tomomasa Ishikawa, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|April 16, 2008
MM2-cortical-type sporadic Creutzfeldt-Jakob disease with early stage cerebral cortical pathology presenting with a rapidly progressive clinical courseYoshiki Niimi, Yasushi Iwasaki, Toshitaka Umemura, et al.
Molecular and Cellular Neurosciences|March 31, 2018
Anti-GM1 ganglioside antibodies modulate membrane-associated sphingomyelin metabolism by altering neutral sphingomyelinase activityAkihiro Ueda, Sayuri Shima, Kenitiroh Murate, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Biochemical and Biophysical Research Communications|December 6, 2022
A pilot study assessing sphingolipids and glycolipids dysmetabolism in idiopathic normal pressure hydrocephalusTatsuro Mutoh, Yoshiki Niimi, Shinji Ito, et al.
Journal of Medical Internet Research|July 22, 2021
Efficacy and Cost-effectiveness of Promotion Methods to Recruit Participants to an Online Screening Registry for Alzheimer Disease Prevention Trials: Observational StudyKenichiro Sato, Yoshiki Niimi, Ryoko Ihara, et al.
Journal of Alzheimer'S Disease : JAD|April 21, 2026
Early adoption of lecanemab in Japan (December 2023-December 2024): Pretreatment diagnostic timelines from the DeSC claims databaseSaki Nakashima, Kenichiro Sato, Yoshiki Niimi, et al.
Biochemical and Biophysical Research Communications|December 28, 2020
Galabiosylceramide is present in human cerebrospinal fluidHisako Akiyama, Mitsuko Ide, Toshiyuki Yamaji, et al.
Molecular and Cellular Biochemistry|July 22, 2025
Cerebrospinal fluid sphingolipid and sterol metabolite profiles of neurologically normal subjectsYoshiki Niimi, Akihiro Ueda, Hisako Akiyama, et al.
Journal of Parkinson'S Disease|November 20, 2020
Cerebrospinal Fluid Profiles in Parkinson's Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 FragmentYoshiki Niimi, Yasuaki Mizutani, Hisako Akiyama, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
SWI and T2*-GRE Microhemorrhage Counts in Anti-Amyloid Therapy Eligibility: A Real-World-Calibrated Simulation StudyKenichiro Sato, Ryoko Ihara, Masanori Kurihara, et al.
Neurology|December 10, 2013
Anti-neutral glycolipid antibodies in encephalomyeloradiculoneuropathySayuri Shima, Naoki Kawamura, Tomomasa Ishikawa, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|April 16, 2008
MM2-cortical-type sporadic Creutzfeldt-Jakob disease with early stage cerebral cortical pathology presenting with a rapidly progressive clinical courseYoshiki Niimi, Yasushi Iwasaki, Toshitaka Umemura, et al.
Molecular and Cellular Neurosciences|March 31, 2018
Anti-GM1 ganglioside antibodies modulate membrane-associated sphingomyelin metabolism by altering neutral sphingomyelinase activityAkihiro Ueda, Sayuri Shima, Kenitiroh Murate, et al.
Pageof 8